Discover comprehensive details about Ravulizumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

The appraisal committee considered evidence submitted by Alexion Pharmaceuticals, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee ...

Credit: Getty Images. The phase 3 CHAMPION-NMOSD trial evaluated ravulizumab-cwvz, a C5 complement inhibitor, in 58 adults with AQP4 Ab+ NMOSD. Positive high-level results were announced from a phase ...

Please provide your email address to receive an email when new articles are posted on . Ravulizumab did not improve functional status or survival in patients with ALS. The phase 3 trial ended early ...

Ravulizumab (Ultomiris), a terminal complement C5 inhibitor, did not improve functional status and survival in patients with amyotrophic lateral sclerosis (ALS), the phase III CHAMPION-ALS trial ...

Credit: Shutterstock. The randomized, double-blind, placebo-controlled phase 3 study included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.

Ravulizumab is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria ...

Please provide your email address to receive an email when new articles are posted on . Fewer clinical deterioration events were reported in patients receiving ravulizumab (9.3%) vs. placebo (16.9%).

BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...

These results were obtained from the 32-week prospective, observational cohort REVEAL study among eligible individuals with the rare, chronic blood disorder who wore a digital wearable ...